{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:57:03Z","timestamp":1794967023275,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","award":["FFC#13\/2024"],"award-info":[{"award-number":["FFC#13\/2024"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118558","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:00:45Z","timestamp":1758582045000},"page":"118558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development and application of a multimatrix LC\u2013MS\/MS method for quantifying elexacaftor\u2013tezacaftor\u2013ivacaftor: Expanding therapeutic drug monitoring in cystic fibrosis from systemic circulation to airways and sweat"],"prefix":"10.1016","volume":"192","author":[{"given":"Matteo","family":"Mucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Colarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-2745","authenticated-orcid":false,"given":"Pietro","family":"Ripani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Del Ciotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Collini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8512-1458","authenticated-orcid":false,"given":"Mario","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1409-5261","authenticated-orcid":false,"given":"Antonio","family":"Recchiuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118558_bib1","article-title":"Anti-inflammatory strategies: what remains to be done if infection and mucus stasis are resolved?","volume":"54","author":"Chmiel","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.biopha.2025.118558_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.biopha.2025.118558_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118558_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118558_bib5","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013Tezacaftor\u2013Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118558_bib6","doi-asserted-by":"crossref","first-page":"00082","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.biopha.2025.118558_bib7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor\u2013tezacaftor\u2013ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.biopha.2025.118558_bib8","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1164\/rccm.202310-1836OC","article-title":"Pharmacological improvement of cystic fibrosis transmembrane conductance regulator function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis","volume":"209","author":"Loske","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2025.118558_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.04.013","article-title":"Heterogeneity in response to Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis","author":"Alicandro","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.biopha.2025.118558_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/medicines12010001","article-title":"The pharmacokinetic changes in cystic fibrosis patients population: narrative review","volume":"12","author":"Awaness","year":"2024","journal-title":"Medicines"},{"key":"10.1016\/j.biopha.2025.118558_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-025-01507-2","article-title":"Pharmacokinetics of ivacaftor, tezacaftor, elexacaftor, and lumacaftor in special cystic fibrosis populations: a systematic review","author":"Elzinga","year":"2025","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118558_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"10.1016\/j.biopha.2025.118558_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251323194","article-title":"Cystic fibrosis: new challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor","volume":"19","author":"Terlizzi","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.biopha.2025.118558_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.biopha.2025.118558_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/jpm14101065","article-title":"Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor in adult people with cystic fibrosis","volume":"14","author":"Naehrig","year":"2024","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.biopha.2025.118558_bib16","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bcp.14543","article-title":"Approaching sites of action of drugs in clinical pharmacology: new analytical options and their challenges","volume":"87","author":"Longuesp\u00e9e","year":"2021","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118558_bib17","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.3390\/jcm9092706","article-title":"CFTR modulators: impact on fertility, pregnancy, and lactation in women with cystic fibrosis","volume":"9","author":"Taylor-Cousar","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2025.118558_bib18","article-title":"Pregnancy and neonatal outcome following in utero exposure to CFTR modulators: a multicentre prospective case series","volume":"0","author":"Gautier","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2025.118558_bib19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/FTD.0000000000001231","article-title":"Dried blood spot method development and clinical validation for the analysis of elexacaftor, Elexacaftor-M23, tezacaftor, Tezacaftor-M1, ivacaftor, ivacaftor carboxylate, and hydroxymethyl ivacaftor using LC-MS\/MS","volume":"46","author":"Vonk","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2025.118558_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/pharmaceutics17020200","article-title":"A novel LC-MS\/MS method for the measurement of elexacaftor, tezacaftor and ivacaftor in plasma, dried plasma spot (DPS) and whole blood in volumetric absorptive microsampling (VAMS) devices","volume":"17","author":"Pigliasco","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118558_bib21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s13318-023-00846-4","article-title":"Dried blood Spots\u2014a platform for therapeutic drug monitoring (TDM) and Drug\/Disease response monitoring (DRM)","volume":"48","author":"Zailani","year":"2023","journal-title":"Eur. J. Drug Metab. Pharm."},{"key":"10.1016\/j.biopha.2025.118558_bib22","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.3390\/ijms25094671","article-title":"Insights into inhalation drug disposition: the roles of pulmonary Drug-Metabolizing enzymes and transporters","volume":"25","author":"Dong","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118558_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1274303","article-title":"Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy","volume":"10","author":"Ripani","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.biopha.2025.118558_bib24","unstructured":"EMA. (2023) M10 on bioanalytical method validation\u2014scientific guideline. Eur. Med. Agency Publ. 14."},{"key":"10.1016\/j.biopha.2025.118558_bib25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood Spot\u2013Based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2025.118558_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejps.2015.04.008","article-title":"Dried blood spots for monitoring and individualization of antiepileptic drug treatment","volume":"75","author":"Milosheska","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118558_bib27","article-title":"Clinical effectiveness of Elexacaftor\/Tezacftor\/Ivacaftor in people with cystic fibrosis","author":"Nichols","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2025.118558_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2025.118558_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcf.2024.11.009","article-title":"Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"24","author":"Gramegna","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.biopha.2025.118558_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2025.118558_bib31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2024.12.006","article-title":"Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment","volume":"24","author":"Zemanick","year":"2025","journal-title":"J. Cyst. Fibros."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225007528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225007528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:28:45Z","timestamp":1775780925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225007528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"alternative-id":["S0753332225007528"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118558","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and application of a multimatrix LC\u2013MS\/MS method for quantifying elexacaftor\u2013tezacaftor\u2013ivacaftor: Expanding therapeutic drug monitoring in cystic fibrosis from systemic circulation to airways and sweat","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118558"}}